Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-02-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerpatienttumorinstitutionalct
  Phrases that lowered it: evaluate theto investigatefemalemale18
• Phase: 2 (raises risk) · Design
• Primary purpose: not given (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 6 (raises risk) · Sponsor's track record
• Sponsor's past trials: 3 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clinical Evaluation of the New Hypoxia Imaging Agent HX4 NCT01213030 · started 2009 · scored riskier than 83% of active trials completed
• Tumor Hypoxia With HX4 PET in Several Diseases NCT02584400 · started 2016 · scored riskier than 95% of active trials terminated
• Imaging and Biomarkers of Hypoxia in Solid Tumors NCT01123005 · started 2010 · scored riskier than 99% of active trials terminated
• FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas NCT03730077 · started 2019 · scored riskier than 42% of active trials terminated
• Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water NCT01246869 · started 2013 · scored riskier than 96% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.